The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies DOI Creative Commons
Zhengjia Zhang,

Qingcai Huang,

Liuchunyang Yu

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 12

Published: Jan. 18, 2022

Tumor immune escape is a critical step in the malignant progression of tumors and one major barriers to immunotherapy, making immunotherapy most promising therapeutic approach against today. cells evade surveillance by altering structure their own, or causing abnormal gene protein expression, allowing for unrestricted development invasion. These genetic epigenetic changes have been linked microRNAs (miRNAs), which are important determinants post-transcriptional regulation. perform tumor abnormally expressing related miRNAs, reduce killing effect cells, disrupt response, apoptotic pathways. Consequently, there strong trend toward thoroughly investigating role miRNAs utilizing them treatment. However, because properties an urgent need safe, targeted easily crossed biofilm vehicle protect deliver vivo , exosomes, with excellent biological properties, successfully beaten traditional vehicles provide support miRNA therapy. This review summarizes multiple roles discusses potential applications as anti-tumor Also, this work proposes exosomes new opportunity therapy, novel ideas more effective tumor-fighting approaches based on miRNAs.

Language: Английский

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer DOI Creative Commons
Raquel S. Laureano, Jenny Sprooten,

Isaure Vanmeerbeerk

et al.

OncoImmunology, Journal Year: 2022, Volume and Issue: 11(1)

Published: July 4, 2022

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to paradigm-shifts immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed tumor-associated or -specific antigens (TAAs TSAs), the presence immunostimulatory molecules induce maturation, followed reinfusion into patients. Accordingly, can TAA/TSA-specific CD8+/CD4+ responses. Yet, still shows suboptimal anti-tumor efficacy clinic. Extensive efforts ongoing improve immunogenicity and vaccines, often employing combinatorial chemo-immunotherapy regimens. In Trial Watch, we summarize preclinical clinical developments discuss trends future perspectives DC-based immunotherapy oncological indications.

Language: Английский

Citations

95
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance DOI Creative Commons
Hong Lin, Di Wang, Pinghan Wang

et al.

Molecular Cancer, Journal Year: 2022, Volume and Issue: 21(1)

Published: July 18, 2022

Abstract The resistance of tumor cells to therapy severely impairs the efficacy treatment, leading recurrence and metastasis various cancers. Clarifying underlying mechanisms therapeutic may provide new strategies for overcoming cancer resistance. N6-methyladenosine (m6A) is most prevalent RNA modification in eukaryotes, involved regulation splicing, translation, transport, degradation, stability processing, thus affecting several physiological processes progression. As a novel type multifunctional non-coding RNAs (ncRNAs), circular (circRNAs) have been demonstrated play vital roles anticancer therapy. Currently, accumulating studies revealed mutual m6A circRNAs, their interaction can further influence sensitivity treatment. In this review, we mainly summarized recent advances circRNAs modulation resistance, as well interplay potential mechanisms, providing promising insights future directions reversal cancer.

Language: Английский

Citations

87
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance DOI Open Access
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(19), P. 4562 - 4562

Published: Sept. 20, 2022

Lung cancer is one of the leading causes cancer-related deaths worldwide with a 5-year survival rate less than 18%. Current treatment modalities include surgery, chemotherapy, radiation therapy, targeted and immunotherapy. Despite advances in therapeutic options, resistance to therapy remains major obstacle effectiveness long-term treatment, eventually insensitivity, poor progression-free survival, disease relapse. Resistance mechanisms stem from genetic mutations and/or epigenetic changes, unregulated drug efflux, tumor hypoxia, alterations microenvironment, several other cellular molecular alterations. A better understanding these crucial for targeting factors involved resistance, establishing novel antitumor targets, developing strategies resensitize cells towards treatment. In this review, we summarize diverse driving radiotherapy, immunotherapy, promising help overcome resistance.

Language: Английский

Citations

77
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges DOI Creative Commons

Yuchu Xiang,

Xudong Liu, Yifan Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 9, 2024

Resistance to targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) is a significant challenge the treatment of this disease. The mechanisms resistance are multifactorial include molecular target alterations activation alternative pathways, tumor heterogeneity microenvironment change, immune evasion, immunosuppression. Promising strategies for overcoming development combination therapies, understanding better use novel drug targets, identification biomarkers, modulation so on. Ongoing research into new therapeutic approaches hold great promise improving outcomes patients with NSCLC. Here, we summarize diverse driving NSCLC latest potential promising overcome help who suffer from

Language: Английский

Citations

27
Recent advances in the metal/organic hybrid nanomaterials for cancer theranostics DOI
Zhaoyi Ye, Ying Bao, Zefeng Chen

et al.

Coordination Chemistry Reviews, Journal Year: 2024, Volume and Issue: 504, P. 215654 - 215654

Published: Jan. 20, 2024

Language: Английский

Citations

20
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial DOI Creative Commons
Juanita Lopez, Thomas Powles,

Fadi Braiteh

et al.

Nature Medicine, Journal Year: 2025, Volume and Issue: 31(1), P. 152 - 164

Published: Jan. 1, 2025

Language: Английский

Citations

8
DNA vaccines as promising immuno-therapeutics against cancer: a new insight DOI Creative Commons

Alireza Shariati,

Arya Khezrpour,

Fatemeh Sadat Shariati

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 13, 2025

Cancer is one of the leading causes mortality around world and most our conventional treatments are not efficient enough to combat this deadly disease. Harnessing power immune system target cancer cells appealing methods for therapy. Nucleotide-based vaccines, especially deoxyribonucleic acid (DNA) vaccines viable novel that have recently garnered significant attention. DNA made plasmid molecules encode tumor-associated or tumor-specific antigens (TAAs TSAs), possibly some other immunomodulatory adjuvants such as pro-inflammatory interleukins. Following internalization plasmids into cells, their genes expressed tumor loaded on major histocompatibility be presented T-cells. After T-cells been activated, they will look destroy upon encountering them. As with any treatment, there pros cons associated using these vaccines. They relatively safe, usually well-tolerated, stable, easily mass-produced, cost-effective, stored transported. can induce a systemic response effective both primary metastases. The main disadvantage poor immunogenicity. Several approaches including structural modification, combination therapy (such chemotherapy, radiotherapy, checkpoint blockade (ICB)), incorporation structure studied enhance vaccine’s immunogenicity improve clinical outcome patients. In review, we discuss promising optimization strategies examine important trials regarding

Language: Английский

Citations

3
Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer DOI Creative Commons
Reem Saleh, Rowaida Z. Taha, Salman M. Toor

et al.

Cancer Immunology Immunotherapy, Journal Year: 2020, Volume and Issue: 69(10), P. 1989 - 1999

Published: May 11, 2020

Abstract Despite recent advances in colorectal cancer (CRC) treatment, a large proportion of patients show limited responses to therapies, especially advanced stages. There is an urgent need identify prognostic biomarkers and/or therapeutic targets stages, aiming improve the efficacy current treatments. We aimed determine tumor tissue and circulation CRC patients, with special focus on T cell exhaustion markers. found that mRNA levels PD-1, TIM-3, CTLA-4, TIGIT, CD160, CD244, KLRG1, TOX2, TOX3, Ki-67, PRDM1 were elevated tissues. also investigated differences gene expression between early disease TOX potentially VISTA, SIRT1, Helios suggesting their potential roles progression. In contrast, PD-1 CD160 downregulated VISTA LAG-3 higher than those healthy individuals. Moreover, circulation, CTLA-4 TIGIT reduced Interestingly, both targeting stages could be less effective. Altogether, these findings suggest some markers utilized as for CRC. However, further investigations validations larger cohorts are required confirm findings.

Language: Английский

Citations

102
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells DOI Creative Commons
Reem Saleh, Salman M. Toor, Sarah Khalaf

et al.

Vaccines, Journal Year: 2019, Volume and Issue: 7(4), P. 149 - 149

Published: Oct. 12, 2019

: Triple negative breast cancer (TNBC) is the most aggressive subtype, and it exhibits resistance to common therapies. Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) its ligand, PD-L1, have been approved treat various cancers. However, therapeutic efficacy of PD-1/PD-L1 axis in under clinical investigation. In addition, mechanisms action drugs PD-1 PD-L1 not fully elucidated. this study, we investigated effect human TNBC lines, MDA-MB-231 MDA-MB-468, non-TNBC line, MCF-7, on expression immune checkpoints (ICs) CD4+ T subsets, including regulatory cells (Tregs), using a co-culture system. We also examined blocking or separately combination IC by subsets. found that upregulate ICs PD-1, cytotoxic lymphocyte-associated antigen-4 (CTLA-4), immunoglobulin mucin domain-containing protein 3 (TIM-3) lymphocyte activation gene-3 (LAG-3) co-blockade further upregulates co-expression TIM-3 LAG-3 CD4+CD25+ CD4+CD25+FoxP3+Helios+ Tregs presence cells, but cells. Our results indicate emergence compensatory inhibitory mechanisms, likely mediated activated non-Tregs, which could lead development against blockade.

Language: Английский

Citations

96
Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance DOI
Fang Wei, Dan Wang,

Junyuan Wei

et al.

Cellular and Molecular Life Sciences, Journal Year: 2020, Volume and Issue: 78(1), P. 173 - 193

Published: July 11, 2020

Language: Английский

Citations

95